<DOC>
	<DOCNO>NCT00775450</DOCNO>
	<brief_summary>This multi-center study design evaluate safety immunogenicity Fluzone revaccination elderly adult age ≥ 65 year . Primary Objective : To describe safety profile subject . Secondary Objective : To describe immunogenicity 28 day follow revaccination one three Fluzone formulation .</brief_summary>
	<brief_title>Influenza Vaccine Revaccination Ambulatory Elderly Subjects</brief_title>
	<detailed_description>Subjects previously participate study FID29 invite participate revaccination study . They assign 1 3 group base group previously randomize vaccine receive study FID29 .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Orthomyxoviridae Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Inclusion Criteria : Aged ≥ 65 year day vaccination Enrolled complete study FID29 receive correct vaccine group randomize Informed consent form sign date Able attend schedule visit comply trial procedure Subject medically stable . Exclusion Criteria : Known systemic hypersensitivity vaccine component history lifethreatening reaction trial vaccine vaccine contain substance Participation another clinical trial investigate vaccine , drug , medical device , medical procedure four week precede trial vaccination Planned participation another clinical trial present trial period Known suspect congenital acquire immunodeficiency , immunosuppressive therapy anticancer chemotherapy radiation therapy within precede 6 month , longterm systemic corticosteroid therapy Chronic illness , stage could interfere trial conduct completion , opinion investigator Current alcohol abuse drug addiction may interfere subject 's ability comply trial procedure Receipt blood bloodderived product past 3 month , might interfere assessment immune response Receipt vaccination 4 week precede trial vaccination Planned receipt vaccine 4 week follow trial vaccination Known human immunodeficiency virus ( HIV ) , hepatitis B ( HBs ) antigen , Hepatitis C seropositivity . Previous vaccination influenza past 6 month trial vaccine another vaccine Thrombocytopenia , bleed disorder anticoagulant 3 week precede inclusion contraindicate intramuscular ( IM ) vaccination Subject deprive freedom administrative court order , emergency setting , hospitalize without his/her consent Neoplastic disease hematologic malignancy , ( except localize skin prostate cancer stable time vaccination absence therapy , well subject history neoplastic disease disease free ≥ 5 year ) . Personal family history GuillainBarré Syndrome .</criteria>
	<gender>All</gender>
	<minimum_age>65 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2013</verification_date>
	<keyword>Influenza</keyword>
	<keyword>Orthomyxovirus Infection</keyword>
	<keyword>Inactivated Split-virion influenza vaccine</keyword>
	<keyword>Elderly</keyword>
</DOC>